€40m for Treg starver start-up

The Paris-based biotech develops immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases. Egle Therapeutics was founded in 2020 by biotech entrepreneur Luc Boblet and immunologist Eliane Piaggio, INSERM Research Director and Head of the Translational Immunotherapy Team at Institut Curie. Now, the start-up has €40m in the bank to drive its vision to become a game changer in the field of Tregs immunomodulation through the unique concept of Tregs starving and specifically targeting the most immunosuppressive ones. The new capital will be used primarily to advance two lead assets into the clinic and further strengthen its internal drug pipeline. The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund+, Bioqube Ventures and Takeda Ventures, Inc. also participated in this round.

Closing a substantial Series A of €40M from a high-quality syndicate of renowned investors, as well as a partnership with a top big pharma like the one we have announced with Takeda in June 2020, all in less than 18 months, puts Egle on a trajectory to execute its vision of tackling regulatory T cells to restore immunity in patients suffering from cancer and autoimmune diseases commented CEO Boblet. The funding will give us appropriate resources to push the first Treg starvers into the clinic and we feel very privileged to undertake such responsibility for the benefit of the whole patient community.

Egle represents a strategic investment in a First-In-Class technology platform based on innovative research with novel T regulatory modulations and potential in the oncology and auto-immunity fields, commented Vincent Brichard, Venture Partner at LSP.